User login
Key clinical point: Nearly one third of patients with multiple sclerosis (MS) experience migraine.
Major finding: The pooled prevalence rate of migraine was 31% (P less than .001), which significantly varied across the continents (P less than .001).
Study details: A systematic review and meta-analysis of 11 articles and 12 conference abstracts including a total of 11,372 MS cases.
Disclosures: No funding source was identified. The authors declared no conflicts of interest.
Citation: Mirmosayyeb O et al. J Clin Neuroscience. 2020 Aug 4. doi: 10.1016/j.jocn.2020.06.021.
Key clinical point: Nearly one third of patients with multiple sclerosis (MS) experience migraine.
Major finding: The pooled prevalence rate of migraine was 31% (P less than .001), which significantly varied across the continents (P less than .001).
Study details: A systematic review and meta-analysis of 11 articles and 12 conference abstracts including a total of 11,372 MS cases.
Disclosures: No funding source was identified. The authors declared no conflicts of interest.
Citation: Mirmosayyeb O et al. J Clin Neuroscience. 2020 Aug 4. doi: 10.1016/j.jocn.2020.06.021.
Key clinical point: Nearly one third of patients with multiple sclerosis (MS) experience migraine.
Major finding: The pooled prevalence rate of migraine was 31% (P less than .001), which significantly varied across the continents (P less than .001).
Study details: A systematic review and meta-analysis of 11 articles and 12 conference abstracts including a total of 11,372 MS cases.
Disclosures: No funding source was identified. The authors declared no conflicts of interest.
Citation: Mirmosayyeb O et al. J Clin Neuroscience. 2020 Aug 4. doi: 10.1016/j.jocn.2020.06.021.